Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury
This study has been completed.
First Received: May 7, 2002   Last Updated: July 18, 2006   History of Changes
Sponsor: Eli Lilly and Company
Information provided by: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT00036062
  Purpose

The purpose of this study is to determine whether sivelestat will reduce the amount of time a patient must spend on a ventilator and/or increase the chance of survival of patients with acute lung injury.


Condition Intervention Phase
Respiratory Distress Syndrome, Adult
Acute Lung Injury
Drug: Sivelestat
Phase I
Phase II

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury

Resource links provided by NLM:


Further study details as provided by Eli Lilly and Company:

Estimated Enrollment: 600
Study Start Date: August 2001
Estimated Study Completion Date: December 2002
Detailed Description:

Acute lung injury often develops as a result of severe infection, sepsis, severe injuries, inhalation of foreign substances into the lungs, or pneumonia. The tissues and blood vessels in the lungs become inflamed, and the body does not receive enough oxygen. Patients with this condition are placed on a ventilator to assist with breathing.

Patients entered into this study will be randomly assigned to one of two treatment groups: a sivelestat group or a placebo group. Once entered into the study, patients are monitored for up to 6 months.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • show evidence of acute lung injury
  • be on mechanical ventilation

Exclusion Criteria

  • have undergone certain organ transplants
  • have severe underlying medical problems
  • be unlikely to survive
  • be pregnant or breast-feeding
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00036062

  Hide Study Locations
Locations
United States, Alabama
Birmingham, Alabama, United States
United States, Arizona
Phoenix, Arizona, United States
Tucson, Arizona, United States
United States, California
Sacramento, California, United States
Orange, California, United States
San Diego, California, United States
United States, Colorado
Englewood, Colorado, United States
Denver, Colorado, United States
United States, Connecticut
New Haven, Connecticut, United States
United States, District of Columbia
Washington, District of Columbia, United States
United States, Florida
Bay Pines, Florida, United States
Clearwater, Florida, United States
Ft. Lauderdale, Florida, United States
United States, Georgia
Austell, Georgia, United States
Augusta, Georgia, United States
United States, Illinois
Elk Grove Village, Illinois, United States
Maywood, Illinois, United States
North Chicago, Illinois, United States
Chicago, Illinois, United States
United States, Indiana
Indianapolis, Indiana, United States
United States, Iowa
Des Moines, Iowa, United States
United States, Kansas
Kansas City, Kansas, United States
United States, Kentucky
Louisville, Kentucky, United States
Lexington, Kentucky, United States
United States, Louisiana
Lake Charles, Louisiana, United States
Shreveport, Louisiana, United States
Baton Rouge, Louisiana, United States
United States, Maine
Portland, Maine, United States
United States, Maryland
Towson, Maryland, United States
Baltimore, Maryland, United States
Silver Spring, Maryland, United States
United States, Massachusetts
Boston, Massachusetts, United States
United States, Michigan
Detroit, Michigan, United States
Kalamazoo, Michigan, United States
United States, Missouri
St. Louis, Missouri, United States
United States, New Jersey
Camden, New Jersey, United States
Holmdel, New Jersey, United States
Hackensack, New Jersey, United States
United States, New York
Mineola, New York, United States
Rochester, New York, United States
New York, New York, United States
Bronx, New York, United States
Buffalo, New York, United States
Manhasset, New York, United States
Elmhurst, New York, United States
United States, North Carolina
Greensboro, North Carolina, United States
Winston-Salem, North Carolina, United States
United States, Ohio
Akron, Ohio, United States
Toledo, Ohio, United States
Cincinnati, Ohio, United States
United States, Oregon
Portland, Oregon, United States
United States, Pennsylvania
Allentown, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Hershey, Pennsylvania, United States
United States, Rhode Island
Providence, Rhode Island, United States
United States, South Dakota
Sioux Falls, South Dakota, United States
United States, Tennessee
Nashville, Tennessee, United States
Memphis, Tennessee, United States
United States, Texas
Lubbock, Texas, United States
Houston, Texas, United States
San Antonio, Texas, United States
Irving, Texas, United States
United States, Virginia
Newport News, Virginia, United States
United States, West Virginia
Morgantown, West Virginia, United States
Australia, Australian Capital Territory
Garran, Australian Capital Territory, Australia
Australia, New South Wales
Camperdown, New South Wales, Australia
Kogarah, New South Wales, Australia
St. Leonards, New South Wales, Australia
Wentworthville, New South Wales, Australia
Kingswood, New South Wales, Australia
Australia, Queensland
SouthPort, Queensland, Australia
Australia, South Australia
Bedford Park, South Australia, Australia
Adelaide, South Australia, Australia
Woodville, South Australia, Australia
Australia, Victoria
Parkville, Victoria, Australia
Prahran, Victoria, Australia
Heidelberg, Victoria, Australia
Australia, Western Australia
Perth, Western Australia, Australia
Fremantle, Western Australia, Australia
Belgium
Brugge, Belgium
Liege, Belgium
Brussels, Belgium
Arion, Belgium
Aaist, Belgium
Gent, Belgium
Braine L' Alleud, Belgium
Antwerpen, Belgium
Canada, Alberta
Edmonton, Alberta, Canada
Canada, British Columbia
Vancouver, British Columbia, Canada
Canada, Manitoba
Winnipeg, Manitoba, Canada
Canada, Nova Scotia
Halifax, Nova Scotia, Canada
Canada, Ontario
Hamilton, Ontario, Canada
Toronto, Ontario, Canada
Windsor, Ontario, Canada
Canada, Quebec
Montreal, Quebec, Canada
Sherbrooke, Quebec, Canada
New Zealand
Auckland, New Zealand
Wellington, New Zealand
Hastings, New Zealand
New Zealand, Canterbury
Christchurch, Canterbury, New Zealand
Spain
Madrid, Spain
Badajoz, Spain
Barcelona, Spain
Murcia, Spain
Palma De Mallorca, Spain
Spain, Barcelona
Sabadell, Barcelona, Spain
Manresa, Barcelona, Spain
Spain, Madrid
Getafe, Madrid, Spain
Spain, Murcia
El Palmar, Murcia, Spain
Sponsors and Collaborators
Eli Lilly and Company
  More Information

No publications provided

Study ID Numbers: 6025, H6W-MC-MCAA
Study First Received: May 7, 2002
Last Updated: July 18, 2006
ClinicalTrials.gov Identifier: NCT00036062     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by Eli Lilly and Company:
Sivelestat
acute lung injury

Additional relevant MeSH terms:
ONO 5046
Serine Proteinase Inhibitors
Disease
Molecular Mechanisms of Pharmacological Action
Respiratory Distress Syndrome, Adult
Respiration Disorders
Enzyme Inhibitors
Pharmacologic Actions
Protease Inhibitors
Pathologic Processes
Respiratory Tract Diseases
Syndrome
Lung Diseases

ClinicalTrials.gov processed this record on November 27, 2009